Gottlieb Scott 4

What Happened

• Scott Gottlieb, a member of Pfizer's Board of Directors, was granted 7,686.539 deferred units (derivative award) on 2026-04-23. The units were recorded at $26.67 each, for a total grant value of $205,000. This was an award (grant) of deferred compensation—not an open-market purchase or sale—and is a routine part of non-employee director compensation.

Key Details

• Transaction date and type: 2026-04-23 — Award/Grant (code A), derivative units.
• Price per unit and total value: $26.67 per unit; aggregate value $205,000.
• Shares/units owned after transaction: Not disclosed in the Form 4 filing.
• Footnotes: Each unit equals one phantom share (F1). Grant made under the Pfizer Nonfunded Deferred Compensation and Unit Award Plan for Non-Employee Directors (F2). Units represent deferred director compensation, to be settled in cash or common stock at the director’s election following retirement from the Board (F3).
• Filing timeliness: Form 4 was filed 2026-04-27 for a 2026-04-23 transaction and appears timely (filed within required business-day window).

Context

• These deferred units are a form of director compensation and do not reflect an immediate cash purchase or sale of common stock. They will be settled in cash or shares later, per the director’s election after leaving the Board. Such awards are common for non-employee directors and are generally considered routine compensation rather than a direct signal of short-term market sentiment.